Hepatitis
Test Solution Diagnosis Market Research Report: Information by Disease Type
(Hepatitis A, Hepatitis B, Hepatitis C
and others), Type of Technology [Nucleic Acid Testing (NAT),
Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Diagnostic Tests (RDT),
Chemiluminescence Immunoassay (CLIA), Genotyping and others], End User
(Hospitals, Clinics, Diagnostic Laboratories, Blood Banks, Research Institutes
and others) and Region (the Americas, Europe, Asia-Pacific and the Middle East
& Africa) - Forecast till 2025
Market Snapshot
The
global market for Hepatitis Test Solution Diagnosis can expect to attain a CAGR of 4.9% during
the forecast period (2018-2023), Market Research Future (MRFR) reveals.
Market Drivers and Main
Barriers
Hepatitis
testing helps in determining the genotype of hepatitis that triggers the
ailment. The test also helps understand the method of treatment ideal for the
patient. As different hepatitis viruses cause almost similar symptoms, a series
of diagnostic test is required for identifying the virus, which is the real
cause of the disease. These factors accelerate product demand in the market to
a great extent.
The
global market for hepatitis test solution and diagnosis could expect strong
growth in the subsequent years as a result of the surge in cases of viral
hepatitis as well as autoimmune diseases Increasing healthcare spending is
another critical factor that could work in favor of the market in the near
future.
Throughout
the assessment period, demand from China, South Korea, Turkey, India, Brazil,
and South Africa is most likely to accelerate. As a result, the growing
prospects across developing economies are presumed to support market growth.
The major traction of the market in the future could be in response to the
rising healthcare expenditure and investment, combined with the increasing disposable
income of consumers. Additional factors promoting market growth include surging
medical tourism, coupled with the presence of a huge number of undiagnosed
cases.
Market Segmentation
The
worldwide market for hepatitis test solution/diagnosis has been segmented on
the basis of disease type, technology, end-user, and region.
Depending
on the disease type, the market is segmented into Hepatitis A, Hepatitis B,
Hepatitis C, and others.
The
global hepatitis test solution/diagnosis market, with respect to the
technology, is considered for enzyme-linked immunosorbent assay (ELISA), rapid
diagnostic tests (RDT), polymerase chain reaction (PCR), isothermal nucleic
acid amplification technology (INAAT) and others.
The
various end-users in the market are hospital & diagnostic laboratories,
blood banks, and others.
Browse Complete Report : https://www.marketresearchfuture.com/reports/hepatitis-test-solution-diagnosis-market-7481
Regional Insight
Europe,
Middle East & Africa, Asia Pacific, and the Americas are the primary
markets for hepatitis test solution/diagnosis.
The
Americas is touted to be the leading hepatitis test solution/diagnosis market
in the coming years. The rise in bacterial infection and adoption of clinical
practices for a variety of disease treatment result in the superlative growth
of the regional market. The Centers for Disease Control and Prevention (CDC)
reveals that in 2016, almost 2,967 cases of acute hepatitis C infection were
estimated in the United States (US).
In
2017, Europe covered the second largest share in the global hepatitis test
solution/diagnosis market. Rising HIV cases, increasing kidney problems, and
other infectious diseases lead to hepatitis infection, which accelerates the
product demand in the region. The World Health Organization states that in
2018, close to 14 million people in Europe suffered from Hepatitis C,
accounting for 20% of the worldwide cases of hepatitis. The massive pool of
hepatitis afflicted patients in the region is slated to favor market growth.
Asia
Pacific was identified as the fastest expanding market for hepatitis test
solution/diagnosis in 2017. The regional market benefits from advanced healthcare
infrastructure as well as rising burden of hepatitis infections. The surge in
healthcare spending and increasing penetration of sophisticated clinical
laboratory technologies could also fortify market growth in the ensuing years.
Lastly,
Middle East and Africa was the smallest market for hepatitis test
solution/diagnosis. The region comprises countries with weak economy and poor
healthcare infrastructure along with low per capita income. These factors stunt
the growth of the regional market.
Esteemed Companies
Some
of the most esteemed vendors operating in the worldwide hepatitis test
solution/diagnosis market are Siemens Healthineers (UK), Bio-Rad Laboratories
(US), Diasorin (Italy), Fujirebio, Inc. (Japan), Grifols (USA), Abbott
Laboratories Inc. (US), MedMira, Inc. (US), Biomérieux Sa (France), Roche
Diagnostics (UK), Qiagen (UK), Danaher Corporation (US), among others.
Recent Developments
June 2019
The
World Health Organization (WHO) along with various other hepatitis experts are
demanding large-scale hepatitis testing, mostly in places where resources are
limited. Numerous alternative testing tools such as dried blood spots (DBSs)
and point-of-care (POC) tests are touted to be alternatives to standard
immunoassays which need access to advanced clinical laboratories.
No comments:
Post a Comment